TOP2A overexpression is a strong indicator of poor prognosis in prostate cancer and in nasopharyngeal carcinoma as well as in the subgroup of HER2 negative breast cancer [45–48]. This evidence concerns the gene ERBB2 and nasopharyngeal carcinoma.